drugset / Trial / NCT00628095

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095

Phase 2 Completed 100 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis

Timeline

Start
2008-04-07
Primary completion
2009-02-04
Completion
2009-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CE-224,535 Small molecule 500 mg Oral

Indications